These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9024707)

  • 21. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem.
    Kato T; Fukatsu H; Ito K; Tadokoro M; Ota T; Ikeda M; Isomura T; Ito S; Nishino M; Ishigaki T
    Eur J Nucl Med; 1995 Jan; 22(1):32-9. PubMed ID: 7698152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic tumors: imaging with PET.
    Hawkins RA
    Radiology; 1995 May; 195(2):320-2. PubMed ID: 7724745
    [No Abstract]   [Full Text] [Related]  

  • 24. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.
    Torizuka T; Tamaki N; Inokuma T; Magata Y; Yonekura Y; Tanaka A; Yamaoka Y; Yamamoto K; Konishi J
    J Nucl Med; 1994 Dec; 35(12):1965-9. PubMed ID: 7989978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer.
    Inokuma T; Tamaki N; Torizuka T; Fujita T; Magata Y; Yonekura Y; Ohshio G; Imamura M; Konishi J
    J Nucl Med; 1995 Feb; 36(2):229-35. PubMed ID: 7830119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis of pancreatic carcinoma: role of FDG PET.
    Keogan MT; Tyler D; Clark L; Branch MS; McDermott VG; DeLong DM; Coleman RE
    AJR Am J Roentgenol; 1998 Dec; 171(6):1565-70. PubMed ID: 9843289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
    Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
    Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging a pancreatic carcinoma xenograft model with 11C-acetate: a comparison study with 18F-FDG.
    Zhao C; Chen Z; Ye X; Zhang Y; Zhan H; Aburano T; Tian M; Zhang H
    Nucl Med Commun; 2009 Dec; 30(12):971-7. PubMed ID: 19696689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
    Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H
    JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
    Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
    J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography imaging of pancreatic cancer.
    Krishnamoorthy SK; Jambawaliker S; Saif MW
    JOP; 2014 Mar; 15(2):124-7. PubMed ID: 24618434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
    Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
    Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
    Sun Y; Duan Q; Wang S; Zeng Y; Wu R
    J BUON; 2015; 20(2):452-9. PubMed ID: 26011335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.
    Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Sundaresan SR; Patterson GA; Cooper JD
    AJR Am J Roentgenol; 1997 Feb; 168(2):417-24. PubMed ID: 9016218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.
    Erasmus JJ; Patz EF; McAdams HP; Murray JG; Herndon J; Coleman RE; Goodman PC
    AJR Am J Roentgenol; 1997 May; 168(5):1357-60. PubMed ID: 9129444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
    Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
    J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
    Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
    J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.